ES2365035T3 - Toxinas híbridas que comprenden subunidades de la toxina similar a shiga condensadas con subunidades de la enterotoxina termolábil de escherichia coli y vacunas de las mismas. - Google Patents

Toxinas híbridas que comprenden subunidades de la toxina similar a shiga condensadas con subunidades de la enterotoxina termolábil de escherichia coli y vacunas de las mismas. Download PDF

Info

Publication number
ES2365035T3
ES2365035T3 ES04766245T ES04766245T ES2365035T3 ES 2365035 T3 ES2365035 T3 ES 2365035T3 ES 04766245 T ES04766245 T ES 04766245T ES 04766245 T ES04766245 T ES 04766245T ES 2365035 T3 ES2365035 T3 ES 2365035T3
Authority
ES
Spain
Prior art keywords
toxin
subunit
hybrid
shiga
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04766245T
Other languages
English (en)
Spanish (es)
Inventor
Paul Vermeij
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Application granted granted Critical
Publication of ES2365035T3 publication Critical patent/ES2365035T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES04766245T 2003-07-21 2004-07-16 Toxinas híbridas que comprenden subunidades de la toxina similar a shiga condensadas con subunidades de la enterotoxina termolábil de escherichia coli y vacunas de las mismas. Expired - Lifetime ES2365035T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03077266 2003-07-21
EP03077266 2003-07-21

Publications (1)

Publication Number Publication Date
ES2365035T3 true ES2365035T3 (es) 2011-09-20

Family

ID=34112462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04766245T Expired - Lifetime ES2365035T3 (es) 2003-07-21 2004-07-16 Toxinas híbridas que comprenden subunidades de la toxina similar a shiga condensadas con subunidades de la enterotoxina termolábil de escherichia coli y vacunas de las mismas.

Country Status (8)

Country Link
US (1) US7807184B2 (enExample)
EP (1) EP1648501B1 (enExample)
JP (1) JP4599354B2 (enExample)
AT (1) ATE504312T1 (enExample)
CA (1) CA2531441C (enExample)
DE (1) DE602004032143D1 (enExample)
ES (1) ES2365035T3 (enExample)
WO (1) WO2005011733A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
JP5392528B2 (ja) * 2008-03-25 2014-01-22 独立行政法人産業技術総合研究所 毒素またはウィルス含有汚染液の固相抽出方法および無毒化方法、並びにそれに用いる固相抽出用捕集剤および除染剤
EP2728004B1 (en) * 2008-05-02 2018-08-08 Idemitsu Kosan Co., Ltd. Bacterial toxin vaccine
ES2614803T3 (es) * 2009-01-23 2017-06-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga
US20120269842A1 (en) * 2009-10-09 2012-10-25 South Dakota State University Enterotoxigenic e. coli fusion protein vaccines
JP6497679B2 (ja) * 2013-11-26 2019-04-10 出光興産株式会社 大腸菌症用ワクチン
WO2015100409A2 (en) 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
US11001625B2 (en) 2014-12-10 2021-05-11 Tufts University VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
US11965216B2 (en) 2015-04-07 2024-04-23 Polyskope Labs Detection of one or more pathogens
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12077576B2 (en) 2020-07-02 2024-09-03 Trustees Of Tufts College VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501682D0 (sv) * 1995-05-05 1995-05-05 Jan Holmgren Hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits
EP1057895A1 (de) 1999-06-04 2000-12-06 Lohmann Animal Health GmbH & Co. KG Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung
US20010031485A1 (en) * 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
US7063852B2 (en) 2000-05-19 2006-06-20 The Administrators Of The Tulane Educational Fund Hybrid LT-A/CT-B holotoxin for use as an adjuvant

Also Published As

Publication number Publication date
JP2006527990A (ja) 2006-12-14
CA2531441A1 (en) 2005-02-10
JP4599354B2 (ja) 2010-12-15
US7807184B2 (en) 2010-10-05
DE602004032143D1 (de) 2011-05-19
WO2005011733A1 (en) 2005-02-10
US20080107653A1 (en) 2008-05-08
CA2531441C (en) 2013-04-02
ATE504312T1 (de) 2011-04-15
EP1648501A1 (en) 2006-04-26
EP1648501B1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
US7074416B2 (en) Antigen of hybrid M protein and carrier for group A streptococcal vaccine
ES2365035T3 (es) Toxinas híbridas que comprenden subunidades de la toxina similar a shiga condensadas con subunidades de la enterotoxina termolábil de escherichia coli y vacunas de las mismas.
EA019138B1 (ru) Новые иммуноадъювантные соединения на основе флагеллина и их применение
JP2011512152A (ja) 改善された溶解度を有するＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
KR102071743B1 (ko) 신규의 약독화된 시겔라 생백신
US6716433B1 (en) Group a streptococcal vaccines
US9492523B2 (en) Broadly protective Shigella vaccine based on type III secretion apparatus proteins
US5364774A (en) Treponema hyodysenteriae vaccine
WO1999013084A9 (en) Group a streptococcal vaccines
ES2335668T3 (es) Vacuna de sub-unidad de lawsonia intracellularis.
AU2003232745A1 (en) Brachyspira hyodysenteriae vaccine
AU2003250057A1 (en) Brachyspira hyodysenteriae vaccine
US20220233675A1 (en) Vaccine to protect a pig against actinobacillus pleuropneumoniae
WO2022128243A1 (en) Protective staphylococcal exotoxin vaccine
AU2003251694B2 (en) Strepococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
ES2336684T3 (es) Vacunas de subunidades de ornithobacterium rhinotracheale.
US7794734B2 (en) Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
ES2346064T3 (es) Vacuna subunidad de lawsonia intracellularis.
CN101124241A (zh) 细胞内劳索尼亚菌26kD亚单位疫苗
EP1801217A1 (en) Group A streptococcal vaccines
MX2013001626A (es) Metodo de elaboracion de una vacuna recombinante contra la fiebre de embarque usando proteinas recombinantes de mannheimia haemolytica unidas a cuerpos celulares.